A phase 1, multicenter, dose escalation study of CAT-8015 in patients with relapse or refractory chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), or small lymphocytic lymphoma (SLL).

Trial Profile

A phase 1, multicenter, dose escalation study of CAT-8015 in patients with relapse or refractory chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), or small lymphocytic lymphoma (SLL).

Discontinued
Phase of Trial: Phase I

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs Moxetumomab pasudotox (Primary)
  • Indications B cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia; Lymphoid leukaemia
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Sponsors Cambridge Antibody Technology; MedImmune
  • Most Recent Events

    • 04 Jan 2012 Actual patient number is 11 as reported by ClinicalTrials.gov (NCT00587457).
    • 04 Jan 2012 Actual patient number is 11 as reported by ClinicalTrials.gov (NCT00587457).
    • 04 Jan 2012 Actual patient number is 11 as reported by ClinicalTrials.gov (NCT00587457).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top